- About Us
- Nano-Social Network
- Nano Consulting
- My Account
May 16th, 2005
BioSante Pharmaceuticals (AMEX:BPA) today reported on certain product development highlights and announced financial results for the first quarter ended March 31, 2005.
"The completion of our pivotal Phase III clinical trial of Bio-E-Gel(TM) and two key announcements highlighting the use of our CaP nanotechnology represent important progress for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer.
|Related News Press|
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Strength of hair inspires new materials for body armor January 18th, 2017
Self-assembling particles brighten future of LED lighting January 18th, 2017
Nanoparticle exposure can awaken dormant viruses in the lungs January 17th, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016